Single tyrosine mutation in AAV8 and AAV9 capsids is insufficient to enhance gene delivery to skeletal muscle and heart

Human Gene Therapy Methods

Volumn 23, Issue 1, 2012, Pages 29-37

  Qiao, Chunping ^a   Yuan, Zhenhua ^a   Li, Jianbin ^a   Tang, Ruhang ^a   Li, Juan ^a   Xiao, Xiao ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENO ASSOCIATED VIRAL 8; ADENO ASSOCIATED VIRAL 9; BETA GALACTOSIDASE; LUCIFERASE; TYROSINE; UNCLASSIFIED DRUG; VIRUS VECTOR; CAPSID PROTEIN;

ANIMAL TISSUE; ARTICLE; COPY NUMBER VARIATION; GENE EXPRESSION; GENE MUTATION; GENE TARGETING; GENE THERAPY; GENE TRANSFER; GENE VECTOR; HEART; IN VITRO STUDY; IN VIVO STUDY; MOUSE; MUSCULAR DYSTROPHY; NEWBORN; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REPORTER GENE; SKELETAL MUSCLE; TRANSGENE; VIRUS CAPSID; ADENO ASSOCIATED VIRUS; ANALYSIS OF VARIANCE; ANIMAL; GENETICS; HEART MUSCLE; METABOLISM; METHODOLOGY; MISSENSE MUTATION; SITE DIRECTED MUTAGENESIS;

ANALYSIS OF VARIANCE; ANIMALS; BETA-GALACTOSIDASE; CAPSID PROTEINS; DEPENDOVIRUS; GENE TRANSFER TECHNIQUES; GENETIC THERAPY; LUCIFERASES; MICE; MUSCLE, SKELETAL; MUSCULAR DYSTROPHIES; MUTAGENESIS, SITE-DIRECTED; MUTATION, MISSENSE; MYOCARDIUM; TYROSINE;

EID: 84872008658     PISSN: 19466536     EISSN: 19466544     Source Type: Journal    
DOI: 10.1089/hgtb.2011.229     Document Type: Article

References (53)

1. Ayuso, E., Mingozzi, F., Montane, J., et al. (2010). High AAV vector purity results in serotype-and tissue-independent enhancement of transduction efficiency. Gene Ther. 17, 503-510.
2. Bell, C.L., Vandenberghe, L.H., Bell, P., et al. (2011). The AAV9 receptor and its modification to improve in vivo lung gene transfer in mice. J. Clin. Invest. 121, 2427-2435.
3. Bish, L.T., Morine, K., Sleeper, M.M., et al. (2008). Adenoassociated virus (AAV) serotype 9 provides global cardiac gene transfer superior to AAV1, AAV6, AAV7, and AAV8 in the mouse and rat. Hum. Gene Ther. 19, 1359-1368.
4. Brantly, M.L., Chulay, J.D., Wang, L., et al. (2009). Sustained transgene expression despite T lymphocyte responses in a clinical trial of rAAV1-AAT gene therapy. Proc. Natl. Acad. Sci. U.S.A. 106, 16363-16368.
5. Dalkara, D., Byrne, L.C., Lee, T., et al. (2011). Enhanced gene delivery to the neonatal retina through systemic administration of tyrosine-mutated AAV9. Gene Ther. (in press).
6. Daya, S., and Berns, K.I. (2008). Gene therapy using adenoassociated virus vectors. Clin. Microbiol. Rev. 21, 583-593.
7. Ding, W., Zhang, L., Yan, Z., and Engelhardt, J.F. (2005). Intracellular trafficking of adeno-associated viral vectors. Gene Ther. 12, 873-880. (Pubitemid 40852205)
8. Ferrari, F.K., Samulski, T., Shenk, T., and Samulski, R.J. (1996). Second-strand synthesis is a rate-limiting step for efficient transduction by recombinant adeno-associated virus vectors. J. Virol. 70, 3227-3234. (Pubitemid 26121941)
9. Flotte, T.R., Zeitlin, P.L., Reynolds, T.C., et al. (2003). Phase I trial of intranasal and endobronchial administration of a recombinant adeno-associated virus serotype 2 (rAAV2)-CFTR vector in adult cystic fibrosis patients: A two-part clinical study. Hum. Gene Ther. 14, 1079-1088. (Pubitemid 36851399)
10. Gao, G., Vandenberghe, L.H., and Wilson, J.M. (2005). New recombinant serotypes of AAV vectors. Curr. Gene Ther. 5, 285-297. (Pubitemid 40895013)
11. Gao, G.P., Alvira, M.R., Wang, L., et al. (2002). Novel adenoassociated viruses from rhesus monkeys as vectors for human gene therapy. Proc. Natl. Acad. Sci. U.S.A. 99, 11854-11859. (Pubitemid 34994488)
12. Harper, S.Q., Hauser, M.A., Dellorusso, C., et al. (2002). Modular flexibility of dystrophin: Implications for gene therapy of Duchenne muscular dystrophy. Nat. Med. 8, 253-261. (Pubitemid 34250103)
13. Hauck, B., Zhao, W., High, K., and Xiao, W. (2004). Intracellular viral processing, not single-stranded DNA accumulation, is crucial for recombinant adeno-associated virus transduction. J. Virol. 78, 13678-13686. (Pubitemid 39612766)
14. Hauswirth, W.W., Aleman, T.S., Kaushal, S., et al. (2008). Treatment of Leber congenital amaurosis due to RPE65 mutations by ocular subretinal injection of adeno-associated virus gene vector: Short-term results of a phase I trial. Hum. Gene Ther. 19, 979-990.
15. Inagaki, K., Fuess, S., Storm, T.A., et al. (2006). Robust systemic transduction with AAV9 vectors in mice: Efficient global cardiac gene transfer superior to that of AAV8. Mol. Ther. 14, 45-53. (Pubitemid 43899488)
16. Jayandharan, G.R., Aslanidi, G., Martino, A.T., et al. (2011). Activation of the NF-jB pathway by adeno-associated virus (AAV) vectors and its implications in immune response and gene therapy. Proc. Natl. Acad. Sci. U.S.A. 108, 3743-3748.
17. Kaplitt, M.G., Feigin, A., Tang, C., et al. (2007). Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson's disease: An open label, phase I trial. Lancet 369, 2097-2105. (Pubitemid 46935946)
18. Kauss, M.A., Smith, L.J., Zhong, L., et al. (2011). Enhanced longterm transduction and multilineage engraftment of human hematopoietic stem cells transduced with tyrosine-modified recombinant adeno-associated virus serotype 2. Hum. Gene Ther. 21, 1129-1136.
19. Keiser, N.W., Yan, Z., Zhang, Y., et al. (2010). Unique characteristics of AAV1, 2, and 5 viral entry, intracellular trafficking, and nuclear import define transduction efficiency in HeLa cells. Hum. Gene Ther. 22, 1433-1444.
20. Kornegay, J.N., Li, J., Bogan, J.R., et al. (2010). Widespread muscle expression of an AAV9 human mini-dystrophin vector after intravenous injection in neonatal dystrophin-deficient dogs. Mol. Ther. 18, 1501-1508.
21. Li, M., Jayandharan, G.R., Li, B., et al. (2011). High-efficiency transduction of fibroblasts and mesenchymal stem cells by tyrosine-mutant AAV2 vectors for their potential use in cellular therapy. Hum. Gene Ther. 21, 1527-1543.
22. Li, W., Asokan, A., Wu, Z., et al. (2008). Engineering and selection of shuffled AAV genomes: A new strategy for producing targeted biological nanoparticles. Mol. Ther. 16, 1252-1260. (Pubitemid 351866056)
23. Maguire, A.M., Simonelli, F., Pierce, E.A., et al. (2008). Safety and efficacy of gene transfer for Leber's congenital amaurosis. N. Engl. J. Med. 358, 2240-2248. (Pubitemid 351724453)
24. Maguire, A.M., High, K.A., Auricchio, A., et al. (2009). Agedependent effects of RPE65 gene therapy for Leber's congenital amaurosis: A phase 1 dose-escalation trial. Lancet 374, 1597-1605.
25. Manno, C.S., Chew, A.J., Hutchison, S., et al. (2003). AAVmediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B. Blood 101, 2963-2972. (Pubitemid 36857981)
26. Markusic, D.M., Herzog, R.W., Aslanidi, G.V., et al. (2011). Highefficiency transduction and correction of murine hemophilia B using AAV2 vectors devoid of multiple surface-exposed tyrosines. Mol. Ther. 18, 2048-2056.
27. Mendell, J.R., Rodino-Klapac, L.R., Rosales-Quintero, X., et al. (2009). Limb-girdle muscular dystrophy type 2D gene therapy restores a-sarcoglycan and associated proteins. Ann. Neurol. 66, 290-297.
28. Mendell, J.R., Campbell, K., Rodino-Klapac, L., et al. (2010). Dystrophin immunity in Duchenne's muscular dystrophy. N. Engl. J. Med. 363, 1429-1437.
29. Muzyczka, N., and Warrington, K.H., Jr. (2005). Custom adenoassociated virus capsids: The next generation of recombinant vectors with novel tropism. Hum. Gene Ther. 16, 408-416. (Pubitemid 40647138)
30. Nathwani, A.C., Tuddenham, E.G., Rangarajan, S., et al. (2011). Adenovirus-associated virus vector-mediated gene transfer in hemophilia B. N. Engl. J. Med. 365, 2357-2365.
31. Pang, J.J., Dai, X., Boye, S.E., et al. (2011). Long-term retinal function and structure rescue using capsid mutant AAV8 vector in the rd10 mouse, a model of recessive retinitis pigmentosa. Mol. Ther. 19, 234-242.
32. Petrs-Silva, H., Dinculescu, A., Li, Q., et al. (2009). Highefficiency transduction of the mouse retina by tyrosine-mutant AAV serotype vectors. Mol. Ther. 17, 463-471.
33. Petrs-Silva, H., Dinculescu, A., Li, Q., et al. (2011). Novel properties of tyrosine-mutant AAV2 vectors in the mouse retina. Mol. Ther. 19, 293-301.
34. Pruchnic, R., Cao, B., Peterson, Z.Q., et al. (2000). The use of adeno-associated virus to circumvent the maturationdependent viral transduction of muscle fibers. Hum. Gene Ther. 11, 521-536. (Pubitemid 30134296)
35. Qiao, C., Wang, B., Zhu, X., et al. (2002). A novel gene expression control system and its use in stable, high-titer 293 cell-based adeno-associated virus packaging cell lines. J. Virol. 76, 13015-13027. (Pubitemid 35386985)
36. Qiao, C., Zhang, W., Yuan, Z., et al. (2010). Adeno-associated virus serotype 6 capsid tyrosine-to-phenylalanine mutations improve gene transfer to skeletal muscle. Hum. Gene Ther. 21, 1343-1348.
37. Qiao, C., Yuan, Z., Li, J., et al. (2011). Liver-specific microRNA-122 target sequences incorporated in AAV vectors efficiently inhibits transgene expression in the liver. Gene Ther. 18, 403-410.
38. Samulskim, R.J., Berns, K.I., Tan, M., and Muzyczka, N. (1982). Cloning of adeno-associated virus into pBR322: Rescue of intact virus from the recombinant plasmid in human cells. Proc. Natl. Acad. Sci. U.S.A. 79, 2077-2081. (Pubitemid 12120800)
39. Schaffer, D.V., and Maheshri, N. (2004). Directed evolution of AAV mutants for enhanced gene delivery. Conf. Proc. IEEE Eng. Med. Biol. Soc. 5, 3520-3523. (Pubitemid 40035411)
40. Shen, S., Bryant, K.D., Brown, S.M., et al. (2011). Terminal Nlinked galactose is the primary receptor for adeno-associated virus 9. J. Biol. Chem. 286, 13532-13540.
41. Summerford, C., and Samulski, R.J. (1998). Membrane-associated heparan sulfate proteoglycan is a receptor for adeno-associated virus type 2 virions. J. Virol. 72, 1438-1445. (Pubitemid 28116931)
42. Thomas, C.E., Storm, T.A., Huang, Z., and Kay, M.A. (2004). Rapid uncoating of vector genomes is the key to efficient liver transduction with pseudotyped adeno-associated virus vectors. J. Virol. 78, 3110-3122. (Pubitemid 38314369)
43. Wang, B., Li, J., and Xiao, X. (2000). Adeno-associated virus vector carrying human minidystrophin genes effectively ameliorates muscular dystrophy in mdx mouse model. Proc. Natl. Acad. Sci. U.S.A. 97, 13714-13719.
44. Wang, B., Li, J., Fu, F.H., and Xiao, X. (2009). Systemic human minidystrophin gene transfer improves functions and life span of dystrophin and dystrophin/utrophin-deficient mice. J. Orthop. Res. 27, 421-426.
45. Wang, Z., Zhu, T., Qiao, C., et al. (2005). Adeno-associated virus serotype 8 efficiently delivers genes to muscle and heart. Nat. Biotechnol. 23, 321-328. (Pubitemid 41094420)
46. Wu, Z., Asokan, A., and Samulski, R.J. (2006). Adeno-associated virus serotypes: Vector toolkit for human gene therapy. Mol. Ther. 14, 316-327. (Pubitemid 44184972)
47. Xiao, W., Chirmule, N., Berta, S.C., et al. (1999). Gene therapy vectors based on adeno-associated virus type 1. J. Virol. 73, 3994-4003. (Pubitemid 29189844)
48. Xiao, X., Li, J., and Samulski, R.J. (1998). Production of high-titer recombinant adeno-associated virus vectors in the absence of helper adenovirus. J. Virol. 72, 2224-2232. (Pubitemid 28100780)
49. Yang, L., Jiang, J., Drouin, L.M., et al. (2009). A myocardium tropic adeno-associated virus (AAV) evolved by DNA shuffling and in vivo selection. Proc. Natl. Acad. Sci. U.S.A. 106, 3946-3951.
50. Yu, C.Y., Yuan, Z., Cao, Z., et al. (2009). A muscle-targeting peptide displayed on AAV2 improves muscle tropism on systemic delivery. Gene Ther. 16, 953-962.
51. Zhang, W., Yue, Y., Ghosh, A., et al. (2009). Novel tyrosine mutant vectors expand the utilities of AAV-mediated muscle gene therapy. Poster 453, presented at the annual meeting of the American Society of Gene and Cell Therapy, May 29, 2009, San Diego, CA.
52. Zhong, L., Li, B., Jayandharan, G., et al. (2008a). Tyrosinephosphorylation of AAV2 vectors and its consequences on viral intracellular trafficking and transgene expression. Virology 381, 194-202.
53. Zhong, L., Li, B., Mah, C.S., et al. (2008b). Next generation of adeno-associated virus 2 vectors: point mutations in tyrosines lead to high-efficiency transduction at lower doses. Proc. Natl. Acad. Sci. U.S.A. 105, 7827-7832. (Pubitemid 351872723)